A number of other analysts also recently issued reports on the stock. J P Morgan Chase & Co set a €95.00 ($111.76) price target on shares of Sanofi SA and gave the stock a neutral rating in a report on Thursday, June 22nd. Jefferies Group LLC set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the stock a neutral rating in a report on Monday, May 29th. Credit Suisse Group set a €95.00 ($111.76) price target on shares of Sanofi SA and gave the stock a buy rating in a report on Tuesday, July 4th. Berenberg Bank set a €97.00 ($114.12) price target on shares of Sanofi SA and gave the stock a neutral rating in a report on Thursday, May 11th. Finally, Morgan Stanley set a €91.00 ($107.06) price target on shares of Sanofi SA and gave the stock a buy rating in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of €87.63 ($103.09).
Shares of Sanofi SA (EPA:SAN) opened at 82.26 on Monday. The company has a market capitalization of €103.30 billion and a PE ratio of 11.48. Sanofi SA has a 52 week low of €62.50 and a 52 week high of €92.97. The firm’s 50-day moving average price is €25.48 and its 200 day moving average price is €25.74.
COPYRIGHT VIOLATION NOTICE: This story was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/sanofi-sa-san-given-a-90-00-price-target-by-sp-global-analysts-updated-updated.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi SA and related companies.